Bayer acquires Asklepios BioPharmaceutical in deal worth up to $4bn
Bayer will broaden its innovation base in cell and gene therapy with the acquisition of Asklepios BioPharmaceutical (AskBio): a US biotech working in gene therapies across different therapeutic areas.